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Abstract
The intricate interactions that regulate relationships between endogenous tissue cells and
infiltrating immune cells in the rheumatic joint, particularly in rheumatoid arthritis (RA), were
the subject of the meeting. A better understanding of these interactions might help to define
intervention points that could be used to develop specific therapies. The presentations and
discussions highlighted the fact that, once chronic inflammation is established, several pro-
inflammatory loops involving tumour necrosis factor (TNF)-a and interleukin (IL)-1b can be
defined. Direct cellular contact with stimulated T lymphocytes induces TNF-a and IL-1b in
monocytes which in turn induce functions in fibroblast-like synoviocytes. The latter include
the production of stromal cell-derived factor-1a (SDF-1a) which enhances the expression of
CD40L in T cells, which stimulates SDF-1a production in synoviocytes, which in turn
protects T and B cells from apoptosis and enhances cell recruitment thus favoring
inflammatory processes. IL-1b and TNF-a also induce IL-15 in fibroblast-like synoviocytes,
which induces the production of IL-17 which in turn potentiates IL-1b and TNF-a production
in monocyte-macrophages. This underlines the importance of TNF-a and IL-1b in RA
pathogenesis, and helps explain the efficiency of agents blocking the activity of these
cytokines in RA. Factors able to block the induction of cytokine production (such as
apolipoprotein A-I [apo A-I] and interferon [IFN]-b) might interfere more distally in the
inflammatory process. Furthermore, stimulated T lymphocytes produce osteoclast
differentiation factor (ODF), which triggers erosive functions of osteoclasts. Therefore,
factors capable of affecting the level of T lymphocyte activation, such as IFN-b, IL-15
antagonist, or SDF-1a antagonist, might be of interest in RA therapy.
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apo A-I = apolipoprotein-AI; DC = dendritic cell; HDL = high-density lipoprotein; IFN = interferon; IL = interleukin; MIP = macrophage inflammatory
protein; MMP = metalloproteinase; ODF = osteoclast differentiation factor; OPGL = osteoprotegerin ligand; PI3-K = phosphatidylinositol 3-kinase;
RA = rheumatoid arthritis; SDF-1a = stromal cell-derived factor-1a; SLE = systemic lupus erythematosus; TIMP = tissue inhibitor of metallopro-
teinase; TNF = tumour necrosis factor; WAS = Wiskott-Aldrich syndrome.
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Introduction
The inflammatory site is the locus of many cellular inter-
actions between specific tissue cells and infiltrating cells
of the immune system. In RA many cell types participate in
the pathogenic mechanisms that finally lead to tissue
destruction (cartilage digestion and bone erosion). Amonghttp://arthritis-research.com/content/2/6/472
these cells T lymphocytes may play an important part,
being the most abundant infiltrating cells in the pannus.
Although T lymphocytes are claimed to participate in RA
pathogenesis, knowledge of the mechanisms by which
they exert their pathogenic effect(s) is still elusive. Mono-
cyte-macrophages, the other main type of infiltrating cell in
the pannus, play a crucial role because one of their main
functions is to release various pro-inflammatory cytokines,
including TNF-a, IL-1b, and IL-17, which participate in the
induction of metalloproteinase (MMP) secretion by stromal
cells (fibroblast-like synoviocytes) and osteoprotegerin
ligand (OPGL) expression in osteoblasts. MMPs partici-
pate in cartilage digestion and OPGL induces maturation
of osteoclasts, which are involved in bone resorption. The
meeting was held to highlight some recent key advances
in the intricate interactions between these cells. It was co-
organized by Drs M Feldmann and F Brennan (Kennedy
Institute for Rheumatology, London, UK) and Drs J-M
Dayer and D Burger (Division of Immunology and Allergy,
University Hospital, Geneva, Switzerland); 65 researchers
from eight countries attended the meeting at the Kennedy
Institute for Rheumatology. Three half-day sessions were
organized, each with three main lectures and up to five
short communications followed by a general discussion. 
T cell-macrophage interactions
The subject was introduced by Dr B Bresnihan (Depart-
ment of Rheumatology, St Vincent’s Hospital, Dublin,
Ireland), who, as a clinical rheumatologist, pinpointed the
relevance of T lymphocyte–monocyte–macrophage contact
in RA pathogenesis. As less invasive biopsies are now
possible, synovial tissue samples are more accessible,
allowing direct analysis of cell populations and compari-
son between cell infiltrate and clinical status. The cellular
composition of infiltrates varies from one patient to
another. In general, the number of T lymphocytes in follicu-
lar structures (which resemble germinal centers) around
blood vessels similar to high endothelial venules augments
with time and correlates with disease severity. Monocyte-
macrophages migrate from the vessel through the follicu-
lar structure to the more superficial layer of the pannus
lining-layer, becoming more and more activated (as
revealed by CD68 expression). The radiological outcome
of patients correlates with the number of macrophages in
the synovium. These histological and clinical results pin-
point the importance of T lymphocyte and monocyte-
macrophage infiltrates in terms of cellular composition and
interaction in disease progression and severity.
T lymphocytes are currently thought to play a pivotal part
in the pathogenesis of RA (although this is controversial
[1]). However, knowledge of the mechanism(s) by which
they exert their pathogenic effect remains elusive.
Contact-mediated signaling of monocytes by stimulated T
cells is a potent proinflammatory mechanism that triggers
massive upregulation of the proinflammatory cytokines IL-1
and TNF-a. These cytokines play important roles in RA
and their blockade is an efficient way to diminish symp-
toms in patients. Since the contact-mediated induction of
cytokine production seems to play a major part in RA
pathogenesis, the modulation of this mechanism is of
great therapeutic interest. 
On the basis of the observation that autoreactive T lym-
phocytes are present in the bloodstream of RA patients
and normal subjects, Dr D Burger (Division of Immunology
and Allergy, University Hospital, Geneva, Switzerland)
hypothesized that factors aimed at inhibiting monocyte
activation ought to be present in plasma/serum. We
demonstrated that contact induction of IL-1b and TNF-a
was inhibited by human adult serum but not by serum from
human umbilical cord or fetal calves. The serum inhibitory
factor was identified as apo A-I, a negative acute-phase
protein associated with high-density lipoproteins (HDL).
Although apo A-I binds to stimulated T cells, the interac-
tion of the inhibitory factor with surface molecules involved
in contact activation of monocyte-macrophages (CD69,
b2-integrins and membrane-associated TNF-a) remains to
be demonstrated. In contrast with its action in normal syn-
ovial tissue, apo A-I infuses into the RA synovium, the
immunostaining being particularly intensive in the perivas-
cular regions. These results reveal a novel anti-inflamma-
tory function of apo A-I that might lead to new therapeutic
approaches in chronic inflammatory diseases such as RA.
Dr F Brennan (Kennedy Institute of Rheumatology,
London, UK) demonstrated the importance of cell contact
for TNF-a production by cellular extracts of RA synovial
tissue. In contrast with whole extracts, cellular extracts
that are depleted of T cells do not produce TNF-a,
whereas TNF-a production is restored by fixed, RA T cells.
RA T cells display the activation phenotype, with more
than 85% of them expressing CD45RO. Depending on
the T-cell stimulus, different signaling pathways are
induced in monocyte-macrophages leading to TNF-a pro-
duction. Indeed, activation of T cells by a cytokine cocktail
(IL-15 or IL-2, IL-6 and TNF) or anti-CD3 antibodies leads
to TNF-a induction in monocyte-macrophages involving
activation of NFkB and phosphatidylinositol 3-kinase
(PI3-K), respectively; the engagement of CD45 in mono-
cytes induces TNF-a through both NFkB and PI3-K path-
ways. In monocytes overexpressing IkB (as a result of
adenoviral gene transfer), TNF-a induction by RA T cells
has been shown to be NFkB dependent, whereas TNF-a
production triggered by anti-CD3-stimulated T lympho-
cytes was NFkB independent and mainly PI3-K-depen-
dent. Interestingly, the inhibition of the PI3-K pathway by
wortmannin in RA synovial cells resulted in the over-
production of TNF-a. Together these results suggest that
TNF-a induced through the activation of NFkB promotes
pathogenic inflammatory functions that escape the regula-
tory mechanisms controlled by other signaling pathways.Arthritis Research    Vol 2 No 6 Burger
Therefore, targeting of NFkB in chronic inflammation might
be a promising therapeutic approach. By using monocyte-
macrophages overexpressing IkB (transferred by aden-
ovirus), a group at the Kennedy Institute of Rheumatology
(Drs M Feldmann, C Ciesielski and A Foey) showed that
NFkB is involved in the induction of macrophage inflam-
matory protein (MIP)-1a, IL-6, MMP-1, and MMP-3, to a
lesser extent in the induction of IL-1b and IL-8, but not in
the induction of IL-10, IL-1Ra, IL-11, and tissue inhibitor of
metalloproteinase (TIMP)-1; IL-10 is regulated through the
PI3-K pathway upon induction by CD40 engagement.
Dr J-M Dayer (Division of Immunology and Allergy, Univer-
sity Hospital, Geneva, Switzerland) reported that IFN-b,
which has been approved in multiple sclerosis therapy,
also displays beneficial effects in RA. These in vivo effects
correlate with the modulation of the contact-mediated
induction of cytokine production in monocyte-macro-
phages in which IFN-b inhibits TNF-a and IL-1b produc-
tion and enhances IL-1Ra (IL-1 receptor antagonist)
production. This strengthens the beneficial effect of IFN-b
and also suggests that stromal cells which produce IFN-b
might exert a feedback regulation of cytokine production.
Dr C Chizzolini (Division of Immunology and Allergy, Uni-
versity Hospital, Geneva, Switzerland) reported that polar-
ized T cells (Th1 or Th2) differentially affected the
production of MMP-1 and MMP-9 in macrophages. Inter-
estingly, membrane-associated IL-4 and TNF-a in Th2
cells concurrently induce MMP-1. Although IL-4 has no
effect on freshly isolated peripheral blood mononuclear
cells (PBMCs), it enhances T-cell-contact-mediated MMP-
1 production in monocytes cultured for 7 days with GM-
CSF while it inhibits MMP-9 production. This
demonstrates that in some circumstances, IL-4 might
exacerbate tissue destruction.
The general discussion highlighted the fact that, in vitro,
the type of T-cell stimulus affects the type of products
induced in monocyte-macrophages, suggesting that differ-
ent cell surface molecules (which are differentially
induced) in turn trigger different signalling pathways (eg
NFkB or PI3-K) in monocyte-macrophages.
Other immune interactions
T cells that accumulate in the RA synovium express
cytokines and activation markers that might be related to
pathogenesis. Dr P Lipsky (NIAMS/NIH, Bethesda, MD,
USA) showed that CD4+ T cells isolated from synovial
tissue of RA patients express different patterns of
cytokines and markers as assayed by single cell RT-PCR
[2]. Noticeably, IL-2, IL-4 and IL-6 are not detected. No
correlation has been found for the expression of cytokines,
with the exception of correlations between expression of
ODF (also called RANKL, TRANCE, and OPGL) and
IL-10, and between ODF and TNF-a. There is also a corre-
lation between the expression of IL-10 and CCR7, ODF
and CXCR4, LT-a and CCR6 and IFN-g and CCR5. Inter-
estingly, CXCR4, which is usually a marker of naive
T cells, is present in 76% of synovial CD4+ T cells. This
high level of expression might be due to IL-15, which has
been shown to increase the expression of CXCR4 and the
migration of T cells into the tissue. In synovial tissue
SDF-1a enhances the expression of CD40L in T cells,
which in turn stimulates SDF-1a production in synovio-
cytes, which in turn protects T and B cells from apoptosis
and enhances cell migration. This could induce a self-
maintaining proinflammatory loop, which might be impor-
tant in RA pathogenesis.
IL-17 (which is produced by memory T cells) is present in
both serum and synovial fluid of RA patients, where IL-15
is also expressed. Dr W Malinski (Department of Patho-
physiology and Immunology, Institute of Rheumatology,
Warsaw, Poland) demonstrated that IL-15 but not LPS
(lipopolysaccharide) induces IL-17 production in PBMCs.
IL-17 production is inhibited by both cyclosporin A and
methylprednisolone. In RA synovium, both the membrane-
associated and soluble form of IL-15 are expressed,
mainly in fibroblast-like synoviocytes of the lining layer.
Both IL-1b and TNF-a induce IL-15 in fibroblast-like
synoviocytes; this in turn induces the production of IL-17
in T cells which potentiates IL-1b and TNF-a production in
monocyte-macrophages. Here again there is a potential
self-maintaining proinflammatory loop. The latter could be
interrupted by IL-15 mutant/Fcg2a, an IL-15 antagonist
which prevents collagen-induced arthritis in mice. Further-
more, IL-18 could be involved in this ‘IL-15 loop’, since it
amplifies TNF-a production in monocyte-macrophages
activated by contact with IL-15-stimulated T cells (Dr I
McInnes, Centre for Rheumatic Diseases, Glasgow Royal
Infirmary, Glasgow, UK).
The question of a function for dendritic cells (DCs) in RA
was addressed by Dr D Katz (Department of Immunology,
University College London Medical School, London, UK).
In RA, DCs are mainly present in synovial fluid. Taking the
Wiskott-Aldrich syndrome (WAS) as an example of DC
dysfunction, it has been postulated that microenvironmen-
tal conditions in the RA joint might affect DC function, in
that DCs could activate T cells in an inappropriate (uncon-
trolled) manner. This type of activation could occur
through the engagement of surface molecules such as
CD98 and CD147, since CD147 is expressed in synovial
cells (including T cells).
Systemic lupus erythematosus (SLE) is often described as
a Th2 inflammatory disease, although blocking IFNg has
been useful in animal models [3]. Dr E Liew (Department
of Immunology, University of Glasgow, UK) demonstrates
that injection of IL-18 with or without IL-12 induces SLE-
like symptoms in MRL/lpr mice (proteinurea, glomeru-http://arthritis-research.com/content/2/6/472
lonephritis, and butterfly-like skin lesion around the
muzzle). Although the cytokine profile depends on the
genetic background, IL-18 injected alone induces the Th2
profile, whereas IL-18 and IL-12 injection induces the Th1
profile. This suggests that SLE might involve both Th1 and
Th2 cells.
Dr I McInnes introduced the renal glomerulus as a model
for studying cell contact interactions. Indeed, in the
mesangium, T cells are in contact with epithelial cells.
T cells stimulated with PMA (phorbol myristate acetate)
induce the production of chemokines (MCP-1, RANTES,
IP-10) in epithelial cells in a contact-dependent manner.
This is mainly due to membrane-associated cytokines. In
glomerulonephritis, contact between infiltrating cells
induces ICAM-1 (intercellular adhesion molecule 1) and
IL-6 expression but not MCP-1 production in mesangial
cells. This profile is due to contact between mesangial cells
and  macrophages through the engagement of CD40 and
is enhanced in the presence of TNF-a and IL-1b. Another
system for studying cell–cell interactions in RA was pre-
sented by Dr P Life (Neurology and Rheumatology
Systems, GlaxoWellcome Research and Development,
Stevenage, UK), who adapted the Stamper Woodruff
adhesion assay for use with cryostat tissue sections of RA
synovium or tonsil over which target cells can be incubated
in order to address the question of cytokine production ‘in
situ’. Results show that in such a culture system IL-1b pro-
duction can be induced in the monocytic cell line THP-1.
Another way of interfering with immune cell infiltration is to
hamper their interaction with endothelial cells. Dr A
Hamann (Experimental Rheumatologie, Charite and
Rheumaforschungszentrum, Berlin, Germany) showed that
inhibitors of a4 integrins suppress collagen-induced arthri-
tis in mice, although to a lower extent than steroids.
Whether this effect is only due to blocking of the recruit-
ment of leukocytes into the tissue remains to be deter-
mined. However, since this type of treatment in mice
mobilizes hematopoietic precursors cells to peripheral
blood, but does not lead to a depletion of these cells within
bone marrow, it might be proposed for RA treatment.
T cell anergy in RA
A possible involvement of the jagged/notch genes, which
are differentially induced in RA synovium, was discussed
(Drs F Ponchel and M Ali, Molecular Medicine Unit and
Department of Rheumatology, The University of Leeds,
Leeds, UK). These genes are implicated in mechanisms
involved in T-cell differentiation and thus might be involved
in T-cell anergy. Whether T cells in RA synovium are anergic
has been proposed, challenged and seriously discussed by
many workers. Indeed, RA T cells display some anergic fea-
tures (eg the lack of IL-2 production, stagnation at the G1
stage of the cell cycle, anergic-type Ca2+ fluxes) but as they
are still mediating functions, they cannot be defined as
anergic. This pseudo-anergy may be induced by direct cell–
cell contact of T cells with fibroblast-like synoviocytes which
display an HLA-DR+, CD80– phenotype (Dr G Panayi,
Rheumatology Unit, Guy’s Hospital, London, UK). Indeed, T
cells in RA are CD69+, CD25+, HLA-DR+, and VLA-1+,
they produce small amounts of type 1 cytokines, are poorly
proliferating, are arrested in the G1 stage of the cell cycle,
but are CD45RO+. This is mainly due to contact with
fibroblast-like synoviocytes which induce an upregulation of
CD69 and CD25 in T cells in the absence of cell prolifera-
tion. The premise that fibroblast-like synoviocytes trans-
fected with CD80 triggered T-cell proliferation suggests
that fibroblast-like synoviocytes induce T-cell ‘anergy’
because they lack CD80 expression.
Synoviocytes and bone
The maintenance of bone mass is due to the tight regula-
tion of osteoclast and osteoblast functions, which origi-
nate from hematopoietic and stromal cells, respectively
(Dr G Russell, Department of Human Metabolic and Clin-
ical Biochemistry, University of Sheffield Medical School,
Sheffield, UK). In osteopetrosis, adipocytes accumulate
instead of osteoclasts. Since these two types of cell origi-
nate from the same precursor cell, the accumulation of the
wrong cell might be due to the lack of, or the overexpres-
sion of (a) differentiation factor(s). Since leptin-deficient
mice have enhanced bone mass, leptin might be involved
in this regulatory system. On the other hand, the differenti-
ation of precursor cells into osteoclasts depends on the
interaction of ODF and RANK (receptor-activator of
NFkB), which are members of the TNF and TNF receptor
family, respectively. A defect in this type of factor may lead
to osteopetrosis. In contrast, overexpression of such a
factor might lead to bone resorption. Therefore, action on
this kind of factor might diminish bone erosion in
rheumatic diseases.
The question of factors that trigger osteoclasts to digest
bone during inflammatory conditions was addressed by Dr
S Goldring (Division of Rheumatology and Metabolic
Bone Diseases, Beth Israel Deaconess Medical Center,
Boston, MA, USA). In RA, tartrate-resistant acid phos-
phatase (TRAP), a marker of osteoclasts, is expressed by
cells at the surface of the bone. This suggests that osteo-
clasts are indeed present in RA and might be  responsible
for bone erosion. Osteoclast maturation is regulated by
ODF, which binds to RANK. ODF is produced by both
osteoblastic cells and activated T cells; the latter cells
might be involved in the imbalance of function of osteo-
clasts and osteoblasts in RA. This suggests that the ODF
decoy receptor OPG might be a therapeutic means of
diminishing bone erosion in RA. 
Conclusions
The meeting shed light on several points that are now con-
sensual: (i) in noninfectious conditions such as RA, theinduction of proinflammatory cytokines in monocyte-
macrophages is mainly triggered by cellular contact inter-
actions with stimulated T lymphocytes; (ii) the type of
T-cell stimulus controls the choice of the signaling
pathway in monocyte-macrophages, leading to either ‘con-
trolled’ or ‘uncontrolled’ inflammatory processes; and (iii)
several loops maintain proinflammatory and prodestructive
mechanisms. Therapeutic approaches could be directed
to these mechanisms in the future.
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